K6S Stock Overview
Operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MIRA Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.54 |
| 52 Week High | US$1.85 |
| 52 Week Low | US$0.48 |
| Beta | 0 |
| 11 Month Change | -25.52% |
| 3 Month Change | -38.29% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -25.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| K6S | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -10.0% | -1.3% | 0.8% |
| 1Y | n/a | -17.7% | 6.1% |
Return vs Industry: Insufficient data to determine how K6S performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how K6S performed against the German Market.
Price Volatility
| K6S volatility | |
|---|---|
| K6S Average Weekly Movement | 13.0% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: K6S's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine K6S's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 5 | Erez Aminov | mirapharmaceuticals.com |
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
MIRA Pharmaceuticals, Inc. Fundamentals Summary
| K6S fundamental statistics | |
|---|---|
| Market cap | €7.84m |
| Earnings (TTM) | -€11.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs K6S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| K6S income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.36m |
| Earnings | -US$12.36m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did K6S perform over the long term?
See historical performance and comparison